VIR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 112790 min ago

@ $9.72

Išleistas: 14 vas. 2024 @ 20:10

Grąža: -5.56%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: 6.58 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	1.12M
Vidutinė apimtis	1.03M
Rinkos kapitalizacija	1.25B
EPS	$0 ( 2024-02-22 )
Kita pelno data	( $-1.050 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.00
ATR14	$0.0110 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	De Backer Marianne	Sell	72 995	Common Stock
2024-04-01	Hanly Ann M.	Sell	2 711	Common Stock
2024-03-27	Lee Sung	Sell	6 008	Common Stock
2024-02-22	Hanly Ann M.	Buy	32 500	Common Stock
2024-02-22	Hanly Ann M.	Sell	12 296	Common Stock

INSIDER POWER
-10.23
Last 98 transactions
Buy: 8 177 990 \| Sell: 9 772 896

Tūris Koreliacija

Ilgas: 0.58 (weak)

Trumpas: 0.20 (neutral)

Signal:(74.79) Neutral

Vir Biotechnology Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MMAC	0.954
BOCH	0.943
NETE	0.913
SHSP	0.859
AMRB	0.843
RAVN	0.843
SILC	0.824
DSPG	0.802

10 Labiausiai neigiamai susiję koreliacijos
PAIC	-0.934
RMRM	-0.927
SVOK	-0.922
SVAC	-0.888
ISNS	-0.888
APOP	-0.887
FEYE	-0.874
GAINL	-0.872
SPRT	-0.837
TDAC	-0.828

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Vir Biotechnology Inc Koreliacija - Valiuta/Žaliavos

-0.32
( neutral )

-0.26
( neutral )

0.00
( neutral )

-0.03
( neutral )

-0.09
( neutral )

0.15
( neutral )

Vir Biotechnology Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$86.18M
Bruto pelnas:	$63.96M (74.22 %)
EPS:	$-4.59

FY	2023
Pajamos:	$86.18M
Bruto pelnas:	$63.96M (74.22 %)
EPS:	$-4.59

FY	2022
Pajamos:	$1.58B
Bruto pelnas:	$1.43B (90.74 %)
EPS:	$3.89

FY	2021
Pajamos:	$1.10B
Bruto pelnas:	$1.03B (93.99 %)
EPS:	$4.44

Financial Reports:

No articles found.

Vir Biotechnology Inc

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.